CoChat

Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction

Open access

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Abstract

The farnesoid X receptor (FXR) regulates bile acid, lipid and glucose metabolism. Here we show that treatment of mice with glycine-β-muricholic acid (Gly-MCA) inhibits FXR signalling exclusively in intestine, and improves metabolic parameters in mouse models of obesity. Gly-MCA is a selective high-affinity FXR inhibitor that can be administered orally and prevents, or reverses, high-fat diet-induced and genetic obesity, insulin resistance and hepatic steatosis in mice. The high-affinity FXR agonist GW4064 blocks Gly-MCA action in the gut, and intestine-specific Fxr -null mice are unresponsive to the beneficial effects of Gly-MCA. Mechanistically, the metabolic improvements with Gly-MCA depend on reduced biosynthesis of intestinal-derived ceramides, which directly compromise beige fat thermogenic function. Consequently, ceramide treatment reverses the action of Gly-MCA in high-fat diet-induced obese mice. We further show that FXR signalling in ileum biopsies of humans positively correlates with body mass index. These data suggest that Gly-MCA may be a candidate for the treatment of metabolic disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms10166

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Gly-MCA is an FXR inhibitor. (a) mRNA levels of FXR target genes in lean (n=36) and obese (n=30) human ileum biopsies. Expression was normalized to 18S RNA. Data are presented as mean±s.e.m. Two-tailed Student's t-test. **P<0.01 compared with healthy humans (lean). (b–d) Correlation of Fxr (b), Shp (c) and Fgf19 (d) mRNA expressions in human ileum biopsies with body mass index (BMI). n=66 total individuals. Expression was normalized to 18S RNA. (e) Fxr, Shp and Fgf15 mRNA levels in the ileum of mice after 24 h treatment with Gly-MCA. Expression was normalized to 18S RNA. Vehicle group n=5, Gly-MCA group n=6. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05 compared with vehicle. (f,g) Serum ALT (f) and AST (g) levels of mice after 24 h treatment with Gly-MCA. Vehicle group n=5, Gly-MCA group n=6. Data are presented as mean±s.d. Two-tailed Student's t-test. (h) Ileum and liver Gly-MCA levels. Expression was normalized to 18S RNA. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05, **P<0.01 compared with liver Gly-MCA levels. (i) Tissue Gly-MCA levels as area under the curve (AUC) at the indicated time points 24 h post Gly-MCA (10 mg kg−1) treatment. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. **P<0.01 compared with liver Gly-MCA levels.
Figure 1 Gly-MCA is an FXR inhibitor. (a) mRNA levels of FXR target genes in lean (n=36) and obese (n=30) human ileum biopsies. Expression was normalized to 18S RNA. Data are presented as mean±s.e.m. Two-tailed Student's t-test. **P<0.01 compared with healthy humans (lean). (b–d) Correlation of Fxr (b), Shp (c) and Fgf19 (d) mRNA expressions in human ileum biopsies with body mass index (BMI). n=66 total individuals. Expression was normalized to 18S RNA. (e) Fxr, Shp and Fgf15 mRNA levels in the ileum of mice after 24 h treatment with Gly-MCA. Expression was normalized to 18S RNA. Vehicle group n=5, Gly-MCA group n=6. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05 compared with vehicle. (f,g) Serum ALT (f) and AST (g) levels of mice after 24 h treatment with Gly-MCA. Vehicle group n=5, Gly-MCA group n=6. Data are presented as mean±s.d. Two-tailed Student's t-test. (h) Ileum and liver Gly-MCA levels. Expression was normalized to 18S RNA. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05, **P<0.01 compared with liver Gly-MCA levels. (i) Tissue Gly-MCA levels as area under the curve (AUC) at the indicated time points 24 h post Gly-MCA (10 mg kg−1) treatment. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. **P<0.01 compared with liver Gly-MCA levels.CC BY · PubMed Central
Figure 2 Gly-MCA reverses metabolic dysfunctions in HFD-fed obese mice. (a) The growth curves of body weight of established obese mice fed a HFD treated with vehicle and 10 mg kg−1 Gly-MCA for 5 weeks. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. **P<0.01 compared with vehicle treatment. (b,c) Resting and total O2 consumption (b), and resting and total energy expenditure (c) performed at room temperature in obese mice after 2 weeks of Gly-MCA treatment. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05, **P<0.01 compared with vehicle treatment. (d) Glucose tolerance test (left panel) and the area under the curve (AUC) (right panel) of HFD-induced obese mice treated with vehicle and Gly-MCA for 4 weeks. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. **P<0.01 compared with vehicle treatment. (e) Insulin tolerance test (ITT) of HFD-induced obese mice treated with vehicle and Gly-MCA for 5 weeks. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05, **P<0.01 compared with vehicle treatment. (f) Fasting serum insulin levels. Obese mice fed a HFD were treated with or without Gly-MCA for 5 weeks. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. **P<0.01 compared with vehicle treatment. (g) Representative H&E staining of liver sections. Scale bars, 100 μm. n=5 mice per group. (h) Liver weights. Obese mice fed a HFD were treated with or without Gly-MCA for 5 weeks. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. **P<0.01 compared with vehicle treatment. (i) Liver triglyceride contents. Obese mice fed a HFD were treated with or without Gly-MCA for 5 weeks. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. **P<0.01 compared with vehicle treatment.
Figure 2 Gly-MCA reverses metabolic dysfunctions in HFD-fed obese mice. (a) The growth curves of body weight of established obese mice fed a HFD treated with vehicle and 10 mg kg−1 Gly-MCA for 5 weeks. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. **P<0.01 compared with vehicle treatment. (b,c) Resting and total O2 consumption (b), and resting and total energy expenditure (c) performed at room temperature in obese mice after 2 weeks of Gly-MCA treatment. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05, **P<0.01 compared with vehicle treatment. (d) Glucose tolerance test (left panel) and the area under the curve (AUC) (right panel) of HFD-induced obese mice treated with vehicle and Gly-MCA for 4 weeks. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. **P<0.01 compared with vehicle treatment. (e) Insulin tolerance test (ITT) of HFD-induced obese mice treated with vehicle and Gly-MCA for 5 weeks. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05, **P<0.01 compared with vehicle treatment. (f) Fasting serum insulin levels. Obese mice fed a HFD were treated with or without Gly-MCA for 5 weeks. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. **P<0.01 compared with vehicle treatment. (g) Representative H&E staining of liver sections. Scale bars, 100 μm. n=5 mice per group. (h) Liver weights. Obese mice fed a HFD were treated with or without Gly-MCA for 5 weeks. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. **P<0.01 compared with vehicle treatment. (i) Liver triglyceride contents. Obese mice fed a HFD were treated with or without Gly-MCA for 5 weeks. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. **P<0.01 compared with vehicle treatment.CC BY · PubMed Central
Figure 3 Gly-MCA selectively inhibits intestinal FXR signal and regulates bile acid composition and ceramide metabolism. Mice were treated with or without 10 mg kg−1 Gly-MCA once per day. for 9 weeks concurrently on a HFD. (a) Gly-MCA levels in ileum and liver. n=5 mice per group. Data are presented as mean±s.d. One-way analysis of variance with Tukey's correction. **P<0.01 compared with vehicle-treated mice. ##P<0.01 compared with Gly-MCA levels of ileum after Gly-MCA treatment. (b,c) mRNA levels of FXR target genes in ileum (b) and liver (c). Expression was normalized to 18S RNA. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. **P<0.01 compared with vehicle-treated mice. (d–g) Individual taurine-conjugated bile acids levels in ileum (d), liver (e), serum (f) and gall bladder (g). n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05, **P<0.01 compared with vehicle-treated mice. (h,i) Ileum (h) and serum (i) ceramides levels. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05, **P<0.01 compared with vehicle-treated mice. (j) mRNA levels of ceramide synthesis- and catabolism-related genes in ileum. Expression was normalized to 18S RNA. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05, **P<0.01 compared with vehicle-treated mice. (k) Western blot analysis of SPTLC2 protein expression in ileum of vehicle- and Gly-MCA-treated mice and quantitation of SPTLC2 expression. SPTLC2 protein levels in ileum of vehicle- and Gly-MCA-treated mice. n=3 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05 compared with vehicle-treated mice. Full western blot image is shown in Supplementary Fig. 17. (l) SMPD3 enzyme activities in ileum of vehicle- and Gly-MCA-treated mice. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05 compared with vehicle-treated mice.
Figure 3 Gly-MCA selectively inhibits intestinal FXR signal and regulates bile acid composition and ceramide metabolism. Mice were treated with or without 10 mg kg−1 Gly-MCA once per day. for 9 weeks concurrently on a HFD. (a) Gly-MCA levels in ileum and liver. n=5 mice per group. Data are presented as mean±s.d. One-way analysis of variance with Tukey's correction. **P<0.01 compared with vehicle-treated mice. ##P<0.01 compared with Gly-MCA levels of ileum after Gly-MCA treatment. (b,c) mRNA levels of FXR target genes in ileum (b) and liver (c). Expression was normalized to 18S RNA. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. **P<0.01 compared with vehicle-treated mice. (d–g) Individual taurine-conjugated bile acids levels in ileum (d), liver (e), serum (f) and gall bladder (g). n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05, **P<0.01 compared with vehicle-treated mice. (h,i) Ileum (h) and serum (i) ceramides levels. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05, **P<0.01 compared with vehicle-treated mice. (j) mRNA levels of ceramide synthesis- and catabolism-related genes in ileum. Expression was normalized to 18S RNA. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05, **P<0.01 compared with vehicle-treated mice. (k) Western blot analysis of SPTLC2 protein expression in ileum of vehicle- and Gly-MCA-treated mice and quantitation of SPTLC2 expression. SPTLC2 protein levels in ileum of vehicle- and Gly-MCA-treated mice. n=3 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05 compared with vehicle-treated mice. Full western blot image is shown in Supplementary Fig. 17. (l) SMPD3 enzyme activities in ileum of vehicle- and Gly-MCA-treated mice. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05 compared with vehicle-treated mice.CC BY · PubMed Central
Figure 4 FXR directly regulates ceramide synthesis-related genes. (a,c) mRNA levels of FXR and FXR target genes in ileum. Expression was normalized to 18S RNA. n=5 mice per group. Data are presented as mean±s.d. One-way analysis of variance with Tukey's correction. **P<0.01 compared with vehicle-treated mice. ##P<0.01 compared with TCA-treated mice. (b,d) mRNA levels of ceramide synthesis- and catabolism-related genes in ileum. (a,b) 6 weeks old Fxrfl/fl and FxrΔIE mice fed a chow diet were treated with or without TCA (400 mg kg−1) for 24 h. (c,d) 6-week-old wild-type mice fed a chow diet were treated with vehicle, Gly-MCA (10 mg kg−1), TCA (400 mg kg−1), and TCA (400 mg kg−1)+Gly-MCA (10 mg kg−1) for 24 h. Expression was normalized to 18S RNA. n=5 mice per group. Data are presented as mean±s.d. One-way analysis of variance (ANOVA) with Tukey's correction. **P<0.01 compared with vehicle-treated mice. #P<0.05, ##P<0.01 compared with TCA-treated mice. (e) SMPD3 enzyme activities in ileum of Fxrfl/fl and FxrΔIE mice fed a chow diet were treated with or without TCA (400 mg kg−1) for 24 h. Expression was normalized to 18S RNA. n=5 mice per group. Data are presented as mean±s.d. One-way ANOVA with Tukey's correction. **P<0.01 compared with vehicle-treated mice. ##P<0.01 compared with TCA-treated mice. (f) SMPD3 enzyme activities in ileum of wild-type mice fed a chow diet were treated with vehicle, Gly-MCA (10 mg kg−1), TCA (400 mg kg−1), and TCA (400 mg kg−1)+Gly-MCA (10 mg kg−1) for 24 h. n=5 mice per group. Data are presented as mean±s.d. One-way ANOVA with Tukey's correction. *P<0.05 compared with vehicle-treated mice. #P<0.05 compared with TCA-treated mice.
Figure 4 FXR directly regulates ceramide synthesis-related genes. (a,c) mRNA levels of FXR and FXR target genes in ileum. Expression was normalized to 18S RNA. n=5 mice per group. Data are presented as mean±s.d. One-way analysis of variance with Tukey's correction. **P<0.01 compared with vehicle-treated mice. ##P<0.01 compared with TCA-treated mice. (b,d) mRNA levels of ceramide synthesis- and catabolism-related genes in ileum. (a,b) 6 weeks old Fxrfl/fl and FxrΔIE mice fed a chow diet were treated with or without TCA (400 mg kg−1) for 24 h. (c,d) 6-week-old wild-type mice fed a chow diet were treated with vehicle, Gly-MCA (10 mg kg−1), TCA (400 mg kg−1), and TCA (400 mg kg−1)+Gly-MCA (10 mg kg−1) for 24 h. Expression was normalized to 18S RNA. n=5 mice per group. Data are presented as mean±s.d. One-way analysis of variance (ANOVA) with Tukey's correction. **P<0.01 compared with vehicle-treated mice. #P<0.05, ##P<0.01 compared with TCA-treated mice. (e) SMPD3 enzyme activities in ileum of Fxrfl/fl and FxrΔIE mice fed a chow diet were treated with or without TCA (400 mg kg−1) for 24 h. Expression was normalized to 18S RNA. n=5 mice per group. Data are presented as mean±s.d. One-way ANOVA with Tukey's correction. **P<0.01 compared with vehicle-treated mice. ##P<0.01 compared with TCA-treated mice. (f) SMPD3 enzyme activities in ileum of wild-type mice fed a chow diet were treated with vehicle, Gly-MCA (10 mg kg−1), TCA (400 mg kg−1), and TCA (400 mg kg−1)+Gly-MCA (10 mg kg−1) for 24 h. n=5 mice per group. Data are presented as mean±s.d. One-way ANOVA with Tukey's correction. *P<0.05 compared with vehicle-treated mice. #P<0.05 compared with TCA-treated mice.CC BY · PubMed Central
Figure 5 Gly-MCA prevents mice from HFD-induced obesity and insulin resistance via the inhibition of intestinal FXR. (a) The growth curves of body weight over the course of 8 weeks, of vehicle- and once per day 10 mg kg−1 Gly-MCA-treated Fxrfl/fl mice and FxrΔIE mice, respectively, fed a HFD. n=5 mice per group. Data are presented as mean±s.d. One-way analysis of variance (ANOVA) with Tukey's correction. *P<0.05, **P<0.01 compared with vehicle-treated Fxrfl/fl mice. (b) Fat mass (left panel) and fat mass to lean mass ratio (right panel) of vehicle- and Gly-MCA-treated Fxrfl/fl mice and FxrΔIE mice fed a HFD for 8 weeks. n=5 mice per group. Data are presented as mean±s.d. One-way ANOVA with Tukey's correction. **P<0.01 compared with vehicle-treated Fxrfl/fl mice. (c) Glucose tolerance test (left panel) and the area under the curve (AUC) (right panel) in vehicle- and Gly-MCA-treated Fxrfl/fl mice and FxrΔIE mice after 4 weeks on a HFD. n=5 mice per group. Data are presented as mean±s.d. One-way ANOVA with Tukey's correction. *P<0.05 compared with vehicle-treated Fxrfl/fl mice. (d) Insulin tolerance test (ITT) in vehicle- and Gly-MCA-treated Fxrfl/fl mice and FxrΔIE mice fed a HFD for 5 weeks. n=5 mice per group. Data are presented as mean±s.d. One-way ANOVA with Tukey's correction. *P<0.05 compared with vehicle-treated Fxrfl/fl mice. (e) Fasted serum insulin levels of vehicle- and Gly-MCA-treated Fxrfl/fl mice and FxrΔIE mice fed a HFD for 8 weeks. n=5 mice per group. Data are presented as mean±s.d. One-way ANOVA with Tukey's correction. **P<0.01 compared with vehicle-treated Fxrfl/fl mice.
Figure 5 Gly-MCA prevents mice from HFD-induced obesity and insulin resistance via the inhibition of intestinal FXR. (a) The growth curves of body weight over the course of 8 weeks, of vehicle- and once per day 10 mg kg−1 Gly-MCA-treated Fxrfl/fl mice and FxrΔIE mice, respectively, fed a HFD. n=5 mice per group. Data are presented as mean±s.d. One-way analysis of variance (ANOVA) with Tukey's correction. *P<0.05, **P<0.01 compared with vehicle-treated Fxrfl/fl mice. (b) Fat mass (left panel) and fat mass to lean mass ratio (right panel) of vehicle- and Gly-MCA-treated Fxrfl/fl mice and FxrΔIE mice fed a HFD for 8 weeks. n=5 mice per group. Data are presented as mean±s.d. One-way ANOVA with Tukey's correction. **P<0.01 compared with vehicle-treated Fxrfl/fl mice. (c) Glucose tolerance test (left panel) and the area under the curve (AUC) (right panel) in vehicle- and Gly-MCA-treated Fxrfl/fl mice and FxrΔIE mice after 4 weeks on a HFD. n=5 mice per group. Data are presented as mean±s.d. One-way ANOVA with Tukey's correction. *P<0.05 compared with vehicle-treated Fxrfl/fl mice. (d) Insulin tolerance test (ITT) in vehicle- and Gly-MCA-treated Fxrfl/fl mice and FxrΔIE mice fed a HFD for 5 weeks. n=5 mice per group. Data are presented as mean±s.d. One-way ANOVA with Tukey's correction. *P<0.05 compared with vehicle-treated Fxrfl/fl mice. (e) Fasted serum insulin levels of vehicle- and Gly-MCA-treated Fxrfl/fl mice and FxrΔIE mice fed a HFD for 8 weeks. n=5 mice per group. Data are presented as mean±s.d. One-way ANOVA with Tukey's correction. **P<0.01 compared with vehicle-treated Fxrfl/fl mice.CC BY · PubMed Central
Figure 6 Gly-MCA protects mice from HFD-induced metabolic dysfunctions through inhibition of the intestinal FXR-ceramide axis. (a) The growth curves of body weight over the course of 5 weeks, of vehicle-, 10 mg kg−1 Gly-MCA-, GW4064+Gly-MCA-, ceramide+Gly-MCA-treated mice, respectively, fed a HFD. n=5 mice per group. Data are presented as mean±s.d. One-way analysis of variance (ANOVA) with Tukey's correction. **P<0.01 compared with vehicle-treated mice. (b) Glucose tolerance test (left panel) and the area under the curve (AUC) (right panel) in vehicle-, Gly-MCA-, GW4064+Gly-MCA− and ceramide+Gly-MCA-treated mice concurrently fed a HFD for 4 weeks. n=5 mice per group. Data are presented as mean±s.d. One-way ANOVA with Tukey's correction. *P<0.05, **P<0.01 compared with vehicle-treated mice. #P<0.05, ##P<0.01 compared with Gly-MCA-treated mice. (c) Insulin tolerance test (ITT) in vehicle-, Gly-MCA-, GW4064+Gly-MCA- and ceramide+Gly-MCA-treated mice concurrently fed a HFD for 5 weeks. n=5 mice per group. Data are presented as mean±s.d. One-way ANOVA with Tukey's correction. *P<0.05 compared with vehicle-treated mice. #P<0.05 compared with Gly-MCA-treated mice. (d) Fasting serum insulin levels. The mice were treated with vehicle, Gly-MCA, GW4064+Gly-MCA and ceramide+Gly-MCA for 5 weeks concurrently on a HFD. n=5 mice per group. Data are presented as mean±s.d. One-way ANOVA with Tukey's correction. **P<0.01 compared with vehicle-treated mice. ##P<0.01 compared with Gly-MCA-treated mice. (e) Representative H&E staining of liver sections. Scale bars: 100 μm. n=5 mice per group. (f) Liver triglyceride contents. The mice were treated with vehicle, Gly-MCA−, GW4064+Gly-MCA and ceramide+Gly-MCA for 5 weeks concurrently on a HFD. n=5 mice per group. Data are presented as mean±s.d. One-way ANOVA with Tukey's correction. *P<0.05 compared with vehicle-treated mice. #P<0.05 compared with Gly-MCA-treated mice.
Figure 6 Gly-MCA protects mice from HFD-induced metabolic dysfunctions through inhibition of the intestinal FXR-ceramide axis. (a) The growth curves of body weight over the course of 5 weeks, of vehicle-, 10 mg kg−1 Gly-MCA-, GW4064+Gly-MCA-, ceramide+Gly-MCA-treated mice, respectively, fed a HFD. n=5 mice per group. Data are presented as mean±s.d. One-way analysis of variance (ANOVA) with Tukey's correction. **P<0.01 compared with vehicle-treated mice. (b) Glucose tolerance test (left panel) and the area under the curve (AUC) (right panel) in vehicle-, Gly-MCA-, GW4064+Gly-MCA− and ceramide+Gly-MCA-treated mice concurrently fed a HFD for 4 weeks. n=5 mice per group. Data are presented as mean±s.d. One-way ANOVA with Tukey's correction. *P<0.05, **P<0.01 compared with vehicle-treated mice. #P<0.05, ##P<0.01 compared with Gly-MCA-treated mice. (c) Insulin tolerance test (ITT) in vehicle-, Gly-MCA-, GW4064+Gly-MCA- and ceramide+Gly-MCA-treated mice concurrently fed a HFD for 5 weeks. n=5 mice per group. Data are presented as mean±s.d. One-way ANOVA with Tukey's correction. *P<0.05 compared with vehicle-treated mice. #P<0.05 compared with Gly-MCA-treated mice. (d) Fasting serum insulin levels. The mice were treated with vehicle, Gly-MCA, GW4064+Gly-MCA and ceramide+Gly-MCA for 5 weeks concurrently on a HFD. n=5 mice per group. Data are presented as mean±s.d. One-way ANOVA with Tukey's correction. **P<0.01 compared with vehicle-treated mice. ##P<0.01 compared with Gly-MCA-treated mice. (e) Representative H&E staining of liver sections. Scale bars: 100 μm. n=5 mice per group. (f) Liver triglyceride contents. The mice were treated with vehicle, Gly-MCA−, GW4064+Gly-MCA and ceramide+Gly-MCA for 5 weeks concurrently on a HFD. n=5 mice per group. Data are presented as mean±s.d. One-way ANOVA with Tukey's correction. *P<0.05 compared with vehicle-treated mice. #P<0.05 compared with Gly-MCA-treated mice.CC BY · PubMed Central
Figure 7 Gly-MCA improves beige fat biogenesis via the inhibition of intestinal FXR-ceramide axis. (a) Beige fat thermogenic gene expression in subcutaneous adipose tissue of vehicle- and Gly-MCA-treated Fxrfl/fl and FxrΔIE mice concurrently fed a HFD for 8 weeks. n=5 mice per group. Data are presented as mean±s.d. One-way analysis of variance (ANOVA) with Tukey's correction. *P<0.05, **P<0.01 compared with vehicle-treated mice. (b) Representative UCP1 immunohistochemistry staining of subcutaneous adipose tissue sections from vehicle- and Gly-MCA-treated Fxrfl/fl and FxrΔIE mice concurrently fed a HFD for 8 weeks. n=5 mice per group. (c) Tgr5 and Dio2 mRNA expression in subcutaneous adipose tissue of vehicle- and Gly-MCA-treated Fxrfl/fl and FxrΔIE mice concurrently fed a HFD for 8 weeks. n=5 mice per group. Data are presented as mean±s.d. One-way ANOVA with Tukey's correction. (d) The cAMP levels of beige fat in vehicle- and Gly-MCA-treated Fxrfl/fl and FxrΔIE mice concurrently fed a HFD for 8 weeks. n=5 mice per group. Data are presented as mean±s.d. One-way ANOVA with Tukey's correction. (e) mRNA levels of beige fat thermogenic genes in subcutaneous adipose tissue from vehicle-, Gly-MCA−, GW4064+Gly-MCA− and ceramide+Gly-MCA-treated mice concurrently fed a HFD for 5 weeks. n=5 mice per group. Data are presented as mean±s.d. One-way ANOVA with Tukey's correction. *P<0.05, **P<0.01 compared with vehicle-treated mice. #P<0.05, ##P<0.01 compared with Gly-MCA-treated mice.
Figure 7 Gly-MCA improves beige fat biogenesis via the inhibition of intestinal FXR-ceramide axis. (a) Beige fat thermogenic gene expression in subcutaneous adipose tissue of vehicle- and Gly-MCA-treated Fxrfl/fl and FxrΔIE mice concurrently fed a HFD for 8 weeks. n=5 mice per group. Data are presented as mean±s.d. One-way analysis of variance (ANOVA) with Tukey's correction. *P<0.05, **P<0.01 compared with vehicle-treated mice. (b) Representative UCP1 immunohistochemistry staining of subcutaneous adipose tissue sections from vehicle- and Gly-MCA-treated Fxrfl/fl and FxrΔIE mice concurrently fed a HFD for 8 weeks. n=5 mice per group. (c) Tgr5 and Dio2 mRNA expression in subcutaneous adipose tissue of vehicle- and Gly-MCA-treated Fxrfl/fl and FxrΔIE mice concurrently fed a HFD for 8 weeks. n=5 mice per group. Data are presented as mean±s.d. One-way ANOVA with Tukey's correction. (d) The cAMP levels of beige fat in vehicle- and Gly-MCA-treated Fxrfl/fl and FxrΔIE mice concurrently fed a HFD for 8 weeks. n=5 mice per group. Data are presented as mean±s.d. One-way ANOVA with Tukey's correction. (e) mRNA levels of beige fat thermogenic genes in subcutaneous adipose tissue from vehicle-, Gly-MCA−, GW4064+Gly-MCA− and ceramide+Gly-MCA-treated mice concurrently fed a HFD for 5 weeks. n=5 mice per group. Data are presented as mean±s.d. One-way ANOVA with Tukey's correction. *P<0.05, **P<0.01 compared with vehicle-treated mice. #P<0.05, ##P<0.01 compared with Gly-MCA-treated mice.CC BY · PubMed Central
Figure 8 Treatment with Gly-MCA 5 days specifically inhibits intestinal FXR signalling and lowers ceramide metabolism independent of body weight change. Mice on a HFD were treated with once per day 10 mg kg−1 Gly-MCA for 5 days. (a) Body weights. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. (b,c) Ileum and (b) liver (c) mRNA levels of FXR target genes in ileum. Expression was normalized to 18S RNA. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05, **P<0.01 compared with vehicle-treated mice. (d–f) Ceramide synthesis- and catabolism-related gene mRNA levels in ileum (d), liver (e) and scWAT (f). Expression was normalized to 18S RNA. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05 compared with vehicle-treated mice. (g) SMPD3 enzyme activities in ileum. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05 compared with vehicle-treated mice. (h–j) Ileum (h), portal vein (i) and systematic vein (j) ceramides levels. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05, **P<0.01 compared with vehicle-treated mice.
Figure 8 Treatment with Gly-MCA 5 days specifically inhibits intestinal FXR signalling and lowers ceramide metabolism independent of body weight change. Mice on a HFD were treated with once per day 10 mg kg−1 Gly-MCA for 5 days. (a) Body weights. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. (b,c) Ileum and (b) liver (c) mRNA levels of FXR target genes in ileum. Expression was normalized to 18S RNA. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05, **P<0.01 compared with vehicle-treated mice. (d–f) Ceramide synthesis- and catabolism-related gene mRNA levels in ileum (d), liver (e) and scWAT (f). Expression was normalized to 18S RNA. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05 compared with vehicle-treated mice. (g) SMPD3 enzyme activities in ileum. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05 compared with vehicle-treated mice. (h–j) Ileum (h), portal vein (i) and systematic vein (j) ceramides levels. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05, **P<0.01 compared with vehicle-treated mice.CC BY · PubMed Central
Figure 9 A short-duration 5-day treatment with Gly-MCA specifically increases beige fat thermogenesis and energy expenditure before body weight change. Mice on a HFD were treated with once per day 10 mg kg−1 Gly-MCA for 5 days. (a) Beige fat thermogenic genes expression of scWAT. Expression was normalized to 18S RNA. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05, **P<0.01 compared with vehicle-treated mice. (b,c) Resting and total O2 consumption (b), and resting and total energy expenditure (c) performed at room temperature. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. **P<0.01 compared with vehicle-treated mice. (d) Cumulative food intake per day averaged over 5 days in vehicle- and Gly-MCA-treated obese mice fed a HFD. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test.
Figure 9 A short-duration 5-day treatment with Gly-MCA specifically increases beige fat thermogenesis and energy expenditure before body weight change. Mice on a HFD were treated with once per day 10 mg kg−1 Gly-MCA for 5 days. (a) Beige fat thermogenic genes expression of scWAT. Expression was normalized to 18S RNA. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05, **P<0.01 compared with vehicle-treated mice. (b,c) Resting and total O2 consumption (b), and resting and total energy expenditure (c) performed at room temperature. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test. **P<0.01 compared with vehicle-treated mice. (d) Cumulative food intake per day averaged over 5 days in vehicle- and Gly-MCA-treated obese mice fed a HFD. n=5 mice per group. Data are presented as mean±s.d. Two-tailed Student's t-test.CC BY · PubMed Central
Figure 10 Ceramide compromises ‘browning' function of beige adipocyte. (a,b) mRNA levels of thermogenic related genes in beige adipocytes after 8 h of indicated doses of ceramide treatment (a) or after the indicated time point of 25 μM ceramide treatment (b). Six to seven replicates of three separate experiments. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05, **P<0.01 compared with control. (c) Oxygen consumption rate (OCR) of beige adipocytes after 8 h of indicated concentration ceramide treatment in the presence of 1 μM oligomycin (ATP synthase inhibitor), 1 μM FCCP (uncoupling agent) and 1 μM rotenone (complex I inhibitor) and 1 μM antimycin A (complex III inhibitor). Six replicates of three separate experiments. (d) Basal and maximal respiration of beige adipocytes after 8 h of indicated concentration ceramide treatment. Six replicates of three separate experiments. Data are presented as mean±s.d. Two-tailed Student's t-test. **P<0.01 compared with control. (e) Cell viability after 24 h of the indicated doses of ceramide treatment. (a–e) Six replicates of three separate experiments. Data are presented as mean±s.d. Two-tailed Student's t-test.
Figure 10 Ceramide compromises ‘browning' function of beige adipocyte. (a,b) mRNA levels of thermogenic related genes in beige adipocytes after 8 h of indicated doses of ceramide treatment (a) or after the indicated time point of 25 μM ceramide treatment (b). Six to seven replicates of three separate experiments. Data are presented as mean±s.d. Two-tailed Student's t-test. *P<0.05, **P<0.01 compared with control. (c) Oxygen consumption rate (OCR) of beige adipocytes after 8 h of indicated concentration ceramide treatment in the presence of 1 μM oligomycin (ATP synthase inhibitor), 1 μM FCCP (uncoupling agent) and 1 μM rotenone (complex I inhibitor) and 1 μM antimycin A (complex III inhibitor). Six replicates of three separate experiments. (d) Basal and maximal respiration of beige adipocytes after 8 h of indicated concentration ceramide treatment. Six replicates of three separate experiments. Data are presented as mean±s.d. Two-tailed Student's t-test. **P<0.01 compared with control. (e) Cell viability after 24 h of the indicated doses of ceramide treatment. (a–e) Six replicates of three separate experiments. Data are presented as mean±s.d. Two-tailed Student's t-test.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 566

Metadata

Authors
Jiang, C., Xie, C., Lv, Y., Li, J., Krausz, K. W., Shi, J., Brocker, C. N., Desai, D., Amin, S. G., Bisson, W. H., Liu, Y., Gavrilova, O., Patterson, A. D., & Gonzalez, F. J.
Affiliations
  • National Institutes of Health (US)
  • Peking University (CN)
  • Peking University People's Hospital (CN)
  • Pennsylvania State University (US)
  • Oregon State University (US)
Corresponding author
  • Patterson, Andrew D.
  • Gonzalez, Frank J.
Venue
Nature Communications
Published
2015-12-15
Volume
6
Issue
1
Pages
10166-10166
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2236340720
Cited by
559
References
58
Citations by year
2026: 33 · 2025: 55 · 2024: 54 · 2023: 49 · 2022: 56 · 2021: 78 · 2020: 61 · 2019: 52 · 2018: 39 · 2017: 49 · 2016: 32
FWCI
17.47
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • Greater South Information System
Funders
  • Pennsylvania Department of Health
  • National Natural Science Foundation of China (31401011, 81200626)
  • National Institutes of Health
  • National Cancer Institute
  • National Institute of Environmental Health Sciences (R01ES022186, ES022186)
Topics
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Keywords
farnesoid X receptor, obesity, insulin resistance, hepatic steatosis, ceramide biosynthesis, high-fat diet-induced obesity, bile acid metabolism, GW4064, ileum, metabolic dysfunction
MeSH terms
Receptor, Farnesoid X-Activated, Adolescent, Adult, Aged, Animals, Ceramides, Cholic Acids, Fatty Liver, Female, Glycine, Humans, Ileum, Insulin Resistance, Intestinal Mucosa, Isoxazoles, Liver, Male, Middle Aged, Obesity, Receptors, Cytoplasmic and Nuclear, Mice, Young Adult, Diet, High-Fat

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.